In vivo Distribution of Tiotropium in a Rodent Model Utilizing AP-SMALDI Mass Spectrometry Imaging

Végvári, Ákos; Fehniger, Thomas E.; Dahlbäck, Magnus; Markó-Varga, György; Strupat, Kerstin

doi:10.2174/1573411012666160211235640

Cited by 3 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, important progress has been achieved in tissue preparation combined with novel MSI instrumentation to generate high-quality data. In addition, MSI can now aid in interrogating the spatial distribution of native drug compounds and drug metabolites within tissues at the resolution of a single cell (Sugihara et al 2018;Torok et al 2015Torok et al , 2017Végvári et al 2017). Cold compounds are being measured by MSI, i.e.…”

Section: Drug Imaging By Mass Spectrometrymentioning

confidence: 99%

“…MALDI-MSI is more and more widely used to describing drug distributions in experimental systems. Nevertheless, more than 100 reports have been published where the technology has been used to characterise drug compounds in experimental drug predicting models (Connell et al 2015;Kwon et al 2015;Marko-Varga et al 2012a;Végvári et al 2017). Until recently, only our own studies have described such drug distribution in humans.…”

Section: Drug Imaging By Mass Spectrometrymentioning

confidence: 99%

See 1 more Smart Citation

Clinical protein science in translational medicine targeting malignant melanoma

et al. 2019

View full text Add to dashboard Cite

Melanoma of the skin is the sixth most common type of cancer in Europe and accounts for 3.4% of all diagnosed cancers. More alarming is the degree of recurrence that occurs with approximately 20% of patients lethally relapsing following treatment. Malignant melanoma is a highly aggressive skin cancer and metastases rapidly extend to the regional lymph nodes (stage 3) and to distal organs (stage 4). Targeted oncotherapy is one of the standard treatment for progressive stage 4 melanoma, and BRAF inhibitors (e.g. vemurafenib, dabrafenib) combined with MEK inhibitor (e.g. trametinib) can effectively counter BRAFV600E-mutated melanomas. Compared to conventional chemotherapy, targeted BRAFV600E inhibition achieves a significantly higher response rate. After a period of cancer control, however, most responsive patients develop resistance to the therapy and lethal progression. The many underlying factors potentially causing resistance to BRAF inhibitors have been extensively studied. Nevertheless, the remaining unsolved clinical questions necessitate alternative research approaches to address the molecular mechanisms underlying metastatic and treatment-resistant melanoma. In broader terms, proteomics can address clinical questions far beyond the reach of genomics, by measuring, i.e. the relative abundance of protein products, post-translational modifications (PTMs), protein localisation, turnover, protein interactions and protein function. More specifically, proteomic analysis of body fluids and tissues in a given medical and clinical setting can aid in the identification of cancer biomarkers and novel therapeutic targets. Achieving this goal requires the development of a robust and reproducible clinical proteomic platform that encompasses automated biobanking of patient samples, tissue sectioning and histological examination, efficient protein extraction, enzymatic digestion, mass spectrometry-based quantitative protein analysis by label-free or labelling technologies and/or enrichment of peptides with specific PTMs. By combining data from, e.g. phosphoproteomics and acetylomics, the protein expression profiles of different melanoma stages can provide a solid framework for understanding the biology and progression of the disease. When complemented by proteogenomics, customised protein sequence databases generated from patient-specific genomic and transcriptomic data aid in interpreting clinical proteomic biomarker data to provide a deeper and more comprehensive molecular characterisation of cellular

show abstract

Section: Drug Imaging By Mass Spectrometrymentioning

confidence: 99%

Section: Drug Imaging By Mass Spectrometrymentioning

confidence: 99%

Clinical protein science in translational medicine targeting malignant melanoma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In drug distribution detection, an in vivo experiment in a rodent model utilizing AP MALDI MSI was conducted by Akos Vegvari's team in 2017, revealing the distribution of tiotropium with 10 μm resolution. 105 Meanwhile, AP MALDI imaging mass microscope combined with a relative exposure approach was employed by Tai Rao et al to study pharmacokinetics via octreotide analysis in mouse target tissues. 106 In 2020, three kinds of MSI, desorption electrospray ionization (DESI) MSI, MALDI MSI, and AP MALDI MSI, were employed by Ariful Islam's team for rap mapping of imipramine, chloroquine, and their metabolites in mice kidneys and brains.…”

Section: Applications Using Ap Maldimentioning

confidence: 99%

Nanoparticle-based applications by atmospheric pressure matrix assisted desorption/ionization mass spectrometry

Wang,

Li,

Qian

2023

Nanoscale Adv.

View full text Add to dashboard Cite

show abstract

“…Scanning microprobe matrixassisted laser desorption ionization (SMALDI) mass was invented by Hubert, M. in 2002 (Spengler andHubert, 2002). It was further improved as atmospheric pressure scanning microprobe matrix-assisted laser desorption/ionization mass spectrometry (AP-SMALDI MS) for imaging (Vegvari et al, 2017;Bhandari et al, 2018;Bredehoeft et al, 2019;Kadesch et al, 2020;Mokosch et al, 2021;Mueller et al, 2021;Righetti et al, 2021), while atmospheric pressure MALDI ion sources AP-MALDI have also been developed for MSI (Guenther et al, 2011;Jackson et al, 2018;Keller et al, 2018) and achieved a lateral resolution at 1.4 μm (Kompauer et al, 2017).…”

Section: Classical Ion Sourcesmentioning

confidence: 99%

“…Furthermore, MALDI ion resources can be easily coupled with high-resolution (resolving power) mass analyzers, such as TOF, FT-ICR, and Orbitrap, which provide high mass accuracy for MSI targets. During the recent years, with the developments of some new MALDI ion sources, such as atmosphere pressure AP-MALDI (Kompauer et al, 2017), AP-SMALDI (Vegvari et al, 2017;Bhandari et al, 2018;Bredehoeft et al, 2019;Kadesch et al, 2020;Mokosch et al, 2021;Mueller et al, 2021;Righetti et al, 2021), MALDI-2 (Soltwisch et al, 2015), transmission MALDI-2 (Niehaus et al, 2019), and nano laser probed-based laser desorption ionization (Meng et al, 2020), the lateral resolution of MALDI-MSI will possibly achieve nm or µm level for single cell and even subcellular scale imaging. Finally, the scanning speed of MALDI-MSI largely depends on the speed of MS detection, spectra recording and data processing.…”

Section: General Marks and Conclusionmentioning

confidence: 99%

Advances in MALDI Mass Spectrometry Imaging Single Cell and Tissues

Zhu

Chen

et al. 2022

Front. Chem.

View full text Add to dashboard Cite

Compared with conventional optical microscopy techniques, mass spectrometry imaging (MSI) or imaging mass spectrometry (IMS) is a powerful, label-free analytical technique, which can sensitively and simultaneously detect, quantify, and map hundreds of biomolecules, such as peptides, proteins, lipid, and other organic compounds in cells and tissues. So far, although several soft ionization techniques, such as desorption electrospray ionization (DESI) and secondary ion mass spectrometry (SIMS) have been used for imaging biomolecules, matrix-assisted laser desorption/ionization (MALDI) is still the most widespread MSI scanning method. Here, we aim to provide a comprehensive review of MALDI-MSI with an emphasis on its advances of the instrumentation, methods, application, and future directions in single cell and biological tissues.

show abstract

In vivo Distribution of Tiotropium in a Rodent Model Utilizing AP-SMALDI Mass Spectrometry Imaging

Cited by 3 publications

References 0 publications

Clinical protein science in translational medicine targeting malignant melanoma

Clinical protein science in translational medicine targeting malignant melanoma

Nanoparticle-based applications by atmospheric pressure matrix assisted desorption/ionization mass spectrometry

Advances in MALDI Mass Spectrometry Imaging Single Cell and Tissues

Contact Info

Product

Resources

About